Through our continued investment in different platforms, we are building a portfolio of promising clinical and pre-clinical stage drug candidates. We believe they will improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory.
Differentiated Bispecific Abs Platform – F-star Therapeutics
F-star is a clinical-stage biotech creating a paradigm shift in cancer therapy with an advanced pipeline of immuno-oncology programs.More info
Pioneering mRNA Delivery Platform – pHion Therapeutics
pHion Therapeutics is a therapeutic vaccine development company, utilising its patented peptide-based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response.More info
Respiratory Innovation Centre – (formerly known as Softhale)
The invoX Respiratory Innovation Centre is dedicated to the development of innovative and generic drug-device combination products which use the Softhaler®, a next-generation soft-mist device, to deliver known active pharmaceutical ingredients (APIs), new chemical entities (NCEs) and biomolecules to the lung.More info